Skip to main content
Journal cover image

Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.

Publication ,  Journal Article
Perry, SL; Bohlin, C; Reardon, DA; Desjardins, A; Friedman, AH; Friedman, HS; Vredenburgh, JJ
Published in: J Neurooncol
October 2009

The purpose of this study was to determine the safety of tinzaparin for deep vein thrombosis prophylaxis in newly diagnosed grade III-IV malignant glioma patients. Patients were initiated on daily tinzaparin at a fixed dose of 4,500 IU subcutaneously between 48 h and 4 weeks post-operative for planned duration of 12 months. During chemotherapy cycles, blood counts were monitored weekly and tinzaparin was held if the platelet count decreased to <50,000 and was re-initiated at a platelet count >100,000. Forty patients were enrolled into the study, 35 with glioblastoma multiforme and 5 with anaplastic astrocytoma. Possible attributable toxicity was limited to two patients who developed CNS hemorrhages (one grade 1 and one grade 2) and one patient with an increase in liver enzymes (grade 3). There were no patients with a grade 4 or 5 CNS hemorrhages or systemic hemorrhages >or=grade 2. The median time on prophylactic tinzaparin was 161 days (range of 5 to 601 days). One patient developed a deep venous thrombosis while taking tinzaparin, and three patients developed thromboembolic complications while off tinzaparin. Tinzaparin at a fixed prophylactic dose is safe and may decrease the incidence of thromboembolic complications in brain tumor patients.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Neurooncol

DOI

EISSN

1573-7373

Publication Date

October 2009

Volume

95

Issue

1

Start / End Page

129 / 134

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • Tomography, X-Ray Computed
  • Tinzaparin
  • Pulmonary Embolism
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Heparin, Low-Molecular-Weight
  • Glioma
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Perry, S. L., Bohlin, C., Reardon, D. A., Desjardins, A., Friedman, A. H., Friedman, H. S., & Vredenburgh, J. J. (2009). Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol, 95(1), 129–134. https://doi.org/10.1007/s11060-009-9911-7
Perry, Stephanie L., Cindy Bohlin, David A. Reardon, Annick Desjardins, Allan H. Friedman, Henry S. Friedman, and James J. Vredenburgh. “Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.J Neurooncol 95, no. 1 (October 2009): 129–34. https://doi.org/10.1007/s11060-009-9911-7.
Perry SL, Bohlin C, Reardon DA, Desjardins A, Friedman AH, Friedman HS, et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol. 2009 Oct;95(1):129–34.
Perry, Stephanie L., et al. “Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients.J Neurooncol, vol. 95, no. 1, Oct. 2009, pp. 129–34. Pubmed, doi:10.1007/s11060-009-9911-7.
Perry SL, Bohlin C, Reardon DA, Desjardins A, Friedman AH, Friedman HS, Vredenburgh JJ. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol. 2009 Oct;95(1):129–134.
Journal cover image

Published In

J Neurooncol

DOI

EISSN

1573-7373

Publication Date

October 2009

Volume

95

Issue

1

Start / End Page

129 / 134

Location

United States

Related Subject Headings

  • Venous Thromboembolism
  • Tomography, X-Ray Computed
  • Tinzaparin
  • Pulmonary Embolism
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Heparin, Low-Molecular-Weight
  • Glioma